BridgeBio Pharma, Inc. expected to post a loss of 58 cents a share - Earnings Preview

BridgeBio Pharma

07/08/2026 21:52

BridgeBio Pharma, Inc. BBIO.OQ BBIO.O is expected to  show a rise in quarterly revenue when it reports  results on August 10 for the period ending June 30 2026
The Palo Alto California-based  company is expected to report a 97.8% increase in revenue to $218.743 million from $110.57 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
​LSEG's mean analyst estimate for BridgeBio Pharma, Inc. is for a loss of 58 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $101.50, about 22.6% above its last closing price of $82.80
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.67
-0.68
-0.84
Missed
-23.8
Dec. 31 2026
-0.81
-0.74
-1.00
Missed
-34.7
Sep. 30 2025
-0.88
-0.89
-0.95
Missed
-6.9​
Jun. 30 2025
-0.76
-0.84
-0.95
Missed
-12.6
​​Mar. 31 2025
-0.92
-0.92
-0.88
Beat
4.7
Dec. 31 2024
-1.17
-1.13
-1.40
Missed
-23.8​
Sep. 30 2024
-0.92
-0.98
-1.10
Missed
-12.4
Jun. 30 2024
-1.07
-1.06
-0.39
Beat
63.3
This summary was machine generated August 7 at 20:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)